Pharmaceutical Technology

NOVEMBER 10, 2023

AstraZeneca has posted a profit after tax of $1.37bn for Q3 2023 versus $1.64bn in the same quarter of the previous year, a decline of 16%.

246

246

Pharmaceutical Technology

SEPTEMBER 5, 2022

On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025. Additionally, cardiovascular disease-related acquisitions are not out of the question for AstraZeneca. AstraZeneca’s deal history. In 2019, AstraZeneca entered a $6.9

FDA Approval 287

FDA Approval Clinical Trials Clinical Trials Development 287

Pharmaceutical Technology

MARCH 19, 2024

As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.

Marketing 147

Marketing 147

Pharmaceutical Technology

FEBRUARY 23, 2024

AstraZeneca has announced the conclusion of its acquisition of Gracell Biotechnologies for approximately $1.2bn.

147

147

Pharmaceutical Technology

APRIL 23, 2024

Regulate the complement cascade with AstraZeneca's patented compounds targeting complement Factor D. Treat a range of disorders with this innovative method.

Regulation 130

Regulation 130

Pharmaceutical Technology

SEPTEMBER 6, 2023

The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.

246

246

Pharmaceutical Technology

FEBRUARY 20, 2024

AstraZeneca has concluded the acquisition of clinical-stage biopharmaceutical company Icosavax in a $1.1bn deal.

130

130

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. This includes an upfront payment of $2m from AstraZeneca. Additionally, AstraZeneca will make a potential payment of $385.8m

Development 264

Development Gene Expression Licensing Licensing 264

Bio Pharma Dive

DECEMBER 12, 2020

The deal launches AstraZeneca, a company that has been growing mostly because of newer drugs for cancer and diabetes, into the market for rare disease treatments.

Marketing 362

Marketing Drugs 362

Pharmaceutical Technology

JANUARY 10, 2023

AstraZeneca has signed a definitive agreement to buy US-based biopharmaceutical company CinCor Pharma in a deal valued at about $1.8bn. AstraZeneca stated that the transaction would boost its cardiorenal pipeline by adding baxdrostat. It is currently in clinical development to treat hypertension and primary aldosteronism.

Clinical Trials 243

Clinical Trials Clinical Trials Clinical Development Development 243

Fierce Pharma

APRIL 8, 2024

With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s (ADC's) reach in the U.S.<

Antibody 126

Antibody Drugs 126

Pharmaceutical Technology

NOVEMBER 29, 2022

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. The takeover will offer AstraZeneca access to TCR-Ts, which possess the potential for fighting solid tumours.

Gene Therapy 279

Gene Therapy Gene Development Manufacturing 279

BioSpace

APRIL 24, 2024

Sanofi is dropping its Sjögren’s syndrome candidate due to disappointing Phase II efficacy data, while AstraZeneca is stopping work on some early-stage assets amid a portfolio reprioritization.

90

90

Fierce Pharma

APRIL 1, 2024

Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. The two most influential proxy advisory firms are rallying investors to vote against the 2024 pay proposal for Soriot at the company’s annual general meeting this month.

121

121

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Bio Pharma Dive

JULY 29, 2022

Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.

Sales 280

Sales Medicine Drugs Marketing 280

Pharmaceutical Technology

NOVEMBER 11, 2022

AstraZeneca has reported an 11% rise in total revenue to $10.98bn in the third quarter (Q3) 2022 as against $9.87bn in the year-ago quarter. AstraZeneca CEO Pascal Soriot said: “AstraZeneca continues to see the benefit of our sustained investment in R&D, with 19 major regulatory approvals since our last earnings call.

FDA Approval 242

FDA Approval Clinical Trials Clinical Trials Sales 242

Pharmaceutical Technology

MARCH 14, 2024

AstraZeneca will pay an upfront purchase price of $800m along with a potential regulatory milestone payment of $250m.

130

130

Pharmaceutical Technology

DECEMBER 13, 2023

AstraZeneca has signed a definitive agreement to initiate a tender offer for the acquisition of Icosavax for an equity price of $1.1bn.

130

130

Bio Pharma Dive

AUGUST 29, 2022

The new data position AstraZeneca to significantly expand use of Farxiga in heart failure and compete with Lilly and Boehringer Ingelheim’s rival drug Jardiance.

Drugs 272

Drugs 272

Fierce Pharma

MARCH 6, 2024

AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s s business environment for the life sciences industry, is directing a big chunk of money into the Big Pharma’s home country.

Life Science 145

Life Science Vaccination Vaccine 145

Pharmaceutical Technology

MARCH 17, 2023

The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients.

Research 246

Research Antibody Protein Trials 246

Pharmaceutical Technology

FEBRUARY 7, 2024

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma).

Clinical Development 130

Clinical Development Development 130

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

DECEMBER 15, 2023

The US government is set to receive an additional 230,000 doses of RSV injection Beyfortus from Sanofi and AstraZeneca in January 2024.

147

147

Pharmaceutical Technology

JANUARY 2, 2024

The Chinese NMPA approved AstraZeneca and Sanofi’s Beyfortus to prevent respiratory syncytial virus (RSV) in neonates and infants.

Antibody 130

Antibody 130

Fierce Pharma

APRIL 12, 2024

History is repeating for AstraZeneca CEO Pascal Soriot, who successfully dodged an executive pay revolt at the company’s annual meeting Thursday, echoing a similar situation that played out in 2021 | Out of more than 1.18 million pounds sterling ($23.5 million) for his performance this year.

115

115

Bio Pharma Dive

NOVEMBER 9, 2023

AstraZeneca is paying $185 million upfront to gain access to an experimental GLP-1 drug from China-based biotech Eccogene.

Drugs 164

Drugs 164

pharmaphorum

MARCH 14, 2024

AstraZeneca adds a late-stage rare disease therapy to its pipeline, buying Amolyt Pharma and hypoparathyroidism drug eneboparatide for $800 million upfront.

Drugs 114

Drugs 114

Fierce Pharma

FEBRUARY 27, 2024

AstraZeneca and FibroGen have finally reached the end of the road for their U.S. More than two years after a high-profile FDA rejection, AstraZeneca has backed out of a collaboration with FibroGen for the latter’s oral anemia drug roxadustat in the U.S. collaboration on the oral anemia drug roxadustat.

Trials 126

Trials Drugs 126

Bio Pharma Dive

OCTOBER 15, 2021

The results are a rare positive result for AstraZeneca's experimental drug tremelimumab, which has come up short in a handful of other studies and cancer types.

Trials 281

Trials Drugs 281

Bio Pharma Dive

DECEMBER 30, 2020

The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it.

Vaccination 333

Vaccination Vaccine 333

Bio Pharma Dive

JULY 27, 2021

AstraZeneca aims to help the biotech make a drug based on its findings. After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight.

Drugs 288

Drugs 288

Pharmaceutical Technology

NOVEMBER 9, 2023

Eccogene will receive $185m upfront and up to $1.82bn in payments from AstraZeneca for the small molecule GLP-1 agonist.

Marketing 130

Marketing 130

Bio Pharma Dive

JUNE 4, 2021

drugmaker's longtime finance chief, will move over to a strategy role and run Alexion as a rare disease unit within AstraZeneca. Marc Dunoyer, the U.K.

289

289

Bio Pharma Dive

JANUARY 7, 2022

Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.

Drugs 281

Drugs Licensing Licensing Antibody 281

BioSpace

MARCH 13, 2024

AstraZeneca also gains ownership of AZP-3813, which is being assessed for acromegaly in a Phase I trial. At the center of the deal is Amolyt Pharma’s late-stage candidate eneboparatide for the rare disease hypoparathyroidism.

Trials 117

Trials 117